Logo Image
News|Articles|April 14, 2026

Elahere Combination Achieves 62.7% ORR in Phase 2 Trial for Platinum-Sensitive Ovarian Cancer at SGO 2026

Listen
0:00 / 0:00

Key Takeaways

  • Enrollment included heavily pretreated features, with 49% previously exposed to PARP inhibitors, a group often showing attenuated platinum sensitivity.
  • Response rates were comparable across FRα cutoffs, achieving ~63% confirmed ORR in ≥50% FRα and in the overall FRα ≥25% population.
SHOW MORE

Mirvetuximab soravtansine–carboplatin combination demonstrates strong response rates and manageable safety profile in FRα-positive patients.

Late-breaking results from the Phase 2 IMGN853-0420 trial1 evaluating AbbVie’s Elahere (mirvetuximab soravtansine-gynx) in combination with carboplatin showed significant response rates in patients with folate receptor alpha (FRα)-expressing platinum-sensitive ovarian cancer (PSOC).

The study data, presented at the Society of Gynecologic Oncology (SGO) Annual Meeting 2026, demonstrated a confirmed objective response rate (ORR) of 62.7% in patients with ≥50% FRα expression, meeting the trial’s primary endpoint and highlighting the potential of the antibody-drug conjugate (ADC) across the ovarian cancer treatment continuum.

Study design and patient population

The multicenter, open-label Phase 2 trial2 enrolled 125 patients with FRα-positive recurrent PSOC who had received one prior platinum-based chemotherapy regimen. Patients were treated with Elahere plus carboplatin every three weeks for six to eight cycles, followed by continuation with single-agent Elahere in those without disease progression.

Notably, approximately 49% of participants had prior exposure to PARP inhibitors, a subgroup often associated with reduced responsiveness to subsequent platinum-based therapies.

Efficacy outcomes

Results showed consistent activity across both the primary analysis group and

These findings support further investigation of ADC-based regimens integrated with standard chemotherapy, particularly in patients with FRα-expressing tumors and those previously treated with PARP inhibitors.

the broader study population. In the ≥50% FRα subgroup, ORR reached 62.7% (95% CI, 52.6–72.1), while a similar ORR of 62.4% (95% CI, 53.3–70.9) was observed in the overall population (FRα ≥25%).

At the end of the induction phase, 81% of patients (101 of 125) had not experienced disease progression and continued treatment with mirvetuximab soravtansine monotherapy. Median duration of response across the overall population was 11.2 months.

Additional responses were observed during the continuation phase, with ORR increasing to 68% (95% CI, 59.1–76.1) among patients who transitioned to monotherapy. Among patients previously treated with PARP inhibitors, ORR was 63.9% (95% CI, 50.6–75.8), suggesting activity in a population with limited treatment options.

Safety profile

The safety profile of the combination regimen was consistent with prior studies of Elahere. The most common treatment-related adverse events (AEs) were low-grade ocular effects, including corneal changes, which were reversible in more than 90% of patients.

Grade 3 or higher adverse events occurring in more than 5% of patients included neutropenia (15%), blurred vision (10%), thrombocytopenia (10%), cataract (6%), dry eye (5%), diarrhea (5%), and peripheral sensory neuropathy (5%).

Clinical implications

PSOC remains a challenging disease despite initial responsiveness to chemotherapy, as repeated treatment cycles are often associated with diminishing efficacy and cumulative toxicity.

According to investigators, the combination of Elahere and carboplatin demonstrated robust and durable responses, with continued benefit observed during the maintenance monotherapy phase. These findings support further investigation of ADC-based regimens integrated with standard chemotherapy, particularly in patients with FRα-expressing tumors and those previously treated with PARP inhibitors.

Ongoing development

Elahere is a first-in-class ADC targeting FRα, combining a tumor-directed antibody with a cytotoxic payload designed to selectively kill cancer cells. Elahere is comprised of a folate receptor alpha-binding antibody, cleavable linker, and maytansinoid payload DM4, which eliminates targeted cancer cells.

The FDA granted accelerated approval to Elahere in November 2022 for adults with FRα-positive, platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer who were previously administered one to three systemic treatment regimens. The agency upgraded the regulatory action to a full approval in March 20243.

While the combination regimen evaluated in IMGN853-0420 is not yet approved, the data presented at SGO 2026 further support its potential role as a novel treatment strategy in recurrent PSOC.

References:

1. Konecny GE, Lim PC, Santin AD, et al. Mirvetuximab Soravtansine Plus Carboplatin in Folate Receptor Alpha-Expressing Recurrent Platinum-Sensitive Ovarian Cancer. Presented at: 2026 SGO Annual Meeting; April 10-13, 2025; San Juan, Puerto Rico.

2. Mirvetuximab Soravtansine (MIRV) With Carboplatin in Second-line Treatment of Folate Receptor Alpha (FRα) Expressing, Platinum-sensitive Epithelial Ovarian Cancer. National Library of Medicine. ClinicalTrials.gov. https://clinicaltrials.gov/study/nct05456685

3. James, D. (2024, March 25). FDA Grants Full Approval to Elahere for Patients With Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer. PharmExec.com https://www.pharmexec.com/view/fda-grants-full-approval-to-elahere-for-patients-with-epithelial-ovarian-fallopian-tube-or-primary-peritoneal-cancer

Related Content